Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.5 0.82 (2.07%) Market Cap: 4.92 Bil Enterprise Value: 4.58 Bil PE Ratio: 0 PB Ratio: 18.41 GF Score: 38/100

Apellis Pharmaceuticals, Inc. - Special Call Transcript

Jan 07, 2020 / 01:30PM GMT
Release Date Price: $38.73 (+28.29%)
Operator

Good morning, everyone, and welcome to the Apellis Pharmaceuticals, PEGASUS Top line Phase III Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Tracy Vineis, Vice President of Corporate Affairs at Apellis.

Tracy Vineis
Apellis Pharmaceuticals, Inc. - VP of Corporate Affairs

Good morning, everyone, and thank you for joining us today to discuss the top line results from the PEGASUS pivotal Phase III study, evaluating Pegcetacoplan or APL-2 in adults with Paroxysmal Nocturnal Hemoglobinuria or PNH. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website after the call. Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.

I encourage you to consult the risk factors discussed in our SEC filings for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot